Abstract
Objectives Combined oral contraceptive (COC) use is linked to increased depression risk, potentially via serotonergic pathways. This study examined whether serotonin 2A/2C receptor (5-HT2AR/5-HT2CR) brain binding differs between healthy women using COCs and non-users.
Methods 71 healthy women had been scanned with either [18F]Altanserin (17 COC users, 22 non-users) or [11C]Cimbi-36 Positron Emission Tomography (17 COC users, 15 non-users). Multiple linear regression and latent variable models were used to assess associations between COC use and neocortical 5-HT2AR and subcortical-HT2AR/5-HT2CR binding, respectively.. Analyses were performed on data pooled across both radiotracers and on each tracer, separately.
Results In pooled analyses across both tracers, COC use was not significantly associated with 5-HT2AR binding in the neocortex (−7.7%, 95% CI [−18.9;5.2], p=0.22), nor with 5-HT2AR/5-HT2CR in subcortical regions (−7.8, 95% CI [−21.7;7.7], p=0.31). In [11C]Cimbi-36-only analyses, COC use was associated with −12.6% (95% CI [−22.1;−1.9], p=0.02) lower 5-HT2AR binding in neocortex and −23.5% lower 5-HT2AR/5-HT2CR binding in subcortical regions (95% CI [−35.6;-9.1], p=0.002). No significant differences were observed in the [18F]Altanserin-only analyses.
Conclusion The [11C]Cimbi-36 data indicated lower cortical 5-HT2AR and subcortical 5-HT2AR/5-HT2CR binding in COC users compared to non-users, but this was not observed in the [18F]Altanserin data. This may reflect better signal-to-noise properties of [11C]Cimbi-36 and the fact that it binds more selectively to the high-affinity, biologically active receptor state. These results offer potential mechanistic insights into the depression risk associated with COC use and may have implications for treatments targeting 5-HT2AR/5-HT2CR, underscoring the need for replication and further investigation.
Highlights
1) COC use was associated with lower 5-HT2AR/CR brain binding in Cimbi-36 PET data
2) COC use was not associated with 5-HT2AR brain binding in [18F]Altanserin PET data
3) We speculate if lower 5-HT2AR/CR levels may affect treatments targeting 5-HT2AR/CR
Competing Interest Statement
Declaration of Interest SVL has received honoraria for consultancy work for WCG Clinical Services. The last 3 years, VGF has received honorarium for lectures from: Lundbeck Pharma A/S, Jannsen-Cilag A/S, Gedeon Richter and Ferring Pharmaceuticals A/S. The rest of the authors declare no conflict of interest.
Funding Statement
Funding AK was funded by the Lundbeck Foundation granted by the Danish Psychiatric Society. SVL is funded by the Lundbeck Foundation (R450-2023-1488). The funders had no role in the design and conduct of the study, preparation, review, approval of the manuscript, or the decision to submit the manuscript for publication.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Ethical Committee in the capital region of Denmark approved all study protocols.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors
